Compare Gigacloud Technology Inc (GCT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Sana Biotechnology Inc — how do they compare? Gigacloud Technology Inc trades at $52.01 (market cap $1.84B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Gigacloud Technology Inc is the larger of the two by market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| GCT | SANA | |
|---|---|---|
Market Cap | $1.84B | $1.13B |
Sector | Technology | Health |
52-Week High | $53.25 | $5.92 |
52-Week Low | $25.44 | $2.68 |
Enterprise Value | $1.97B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $51.66, up 0.02% on the day, with a bullish technical outlook supported by moving averages and strong support at $50. The company reported Q2 2026 EPS of $1.16, beating estimates, and maintains a 10.65% net income margin. Revenue growth is projected to rise from $1.29B in 2025 to $1.5B in 2026, with consistent profitability.
The stock presents a compelling opportunity with attractive valuations (P/E 12.25, P/S 1.3) and robust fundamentals, though overbought RSI levels near 84 suggest near-term consolidation risk. Analyst consensus is bullish with 67% buy ratings, but investors should monitor execution risks in European expansion and furniture market volatility.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
